Company intelligence / Profile preview
Fekra Therapeutics
Boston, Massachusetts, United Statesfekratx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Fekra Therapeutics develops novel first-in-class small molecule therapeutics using its proprietary Curiositome platform. Its lead candidate, FT‑01, targets BMX kinase for castration-resistant prostate cancer and has advanced to the clinical stage. The pipeline includes additional programs targeting solid tumors, non-solid tumors, and inflammatory diseases. The company leverages structure-based drug design and AI-driven discovery approaches to address unmet needs in oncology and immunology.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Fekra Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fekra Therapeutics.